Welcome to BMEN 3151 Medical Device Practicum 2022


Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota http://saliterman.umn.edu/

Topics Today

Prof. Steven S. Saliterman

- Team: Peacock Medical
- Highlights of *Medical Device Innovation*
- Team: Raynaud's Phototherapy Device
- Selecting a Medical Device Project & Supplies







First Determine is There A Need?

- Need driven rather than technology driven.
 - Select a clinical area.
 - Observe procedures.
 - $\,{}^{\circ}$ What is the underlying problem?
 - Create a need statement.
 - "A way to reduce back pain with bending"
 - NOT "A device to immobilize the back."
 - Brainstorm solutions.

Prof. Steven S. Salit

• Perform a business analysis.

Adopted from Tolkoff, J, Ideation in Medical Device Development: Finding Clinic Needs, CIMIT CRAASH Course. cimet.org.

Conduct Ideation Sessions

- Understand the problem.
- Define an acceptable degree of *transcendence* deviation from existing ideas and solutions.
- Resources available your Team.
- Structuring the meeting.
- Sources of inspiration.
- Good practices (Osborn, A.T. Applied Imagination)
 - Go for quantity.
 - Encourage unexpected ideas.
 - Defer judgment.

Prof. Steven S. Salit

· Combine and improve ideas.

Rudolph, J. Effectively selecting ideation methods for medical product development. MedTech Intelligence. January 4, 2012.

Provide breaks.

- Create and enforce rules.
 - e.g. stay focused, do not tell stories and do not criticize.
- Getting stuck.

Prof. Steven S. Salite

- Positive motivation and incentive.
- Concluding thoughts.
- Document the session process, people involved, sources of inspiration.

Rudolph, J. Effectively selecting ideation methods for medical product development. MedTech Intelligence. January 4, 2012.

Understand FDA Regulations


- Premarket Requirements
 Product Classification Type I, II or III
 - Premarket Approval (PMA)

 - PMA Supplements.
 Evaluations of the PMA and PMA Supplement Process.
 Humanitarian Device Exemption (HDE).
 510(k) Notification Substantially Equivalent Device
 Assessments of the 510(k) Process
- Post-Market Requirements


Postmarket Surveillance Studies.

- Adverse Event Reporting, Medical Device Tracking, UDI (Unique Device ID)
 National Medical Device Evaluation System.
- Labeling and Manufacturing Compliance and Enforcement

Prof. Steven S. Saliterman










Example – Infusion Pump...





Vasospasm Treatment

Needs Statement

Clinical Problem

Clinical Problem Raynaud's is a disease which presents itself as digital immobility pain, and flushed colour whenever the pa-tient is exposed to cold temperatures. This is thought to be caused by an underlying autointmune is-thought to be caused by an underlying autoimmune is-sue and is commonly genetic. If this disease is not treated by keeping the affected areas warm and clean-ing these areas properly, sores can develop. If these sores are not treated correctly gangrene or open wounds may develop. This can be life threatening if not properly treated. This disease is guide common. This disease typically does not result in death, however the sores that develop as a result of the reduced blood flow can be life threatening. The symptoms can some-times be reduced with calcium channel blockers and vasodilators; however, the effectiveness of these drugs is commonly lower than hoped and may result in side effects for many patients.

"Patients suffering from Raynaud's need an effective way to reduce Raynaud's symptoms without drugs, in a cost effective manor with less potential side-effects."

Market Analysis

If we assume that one in five people with Raynaud's will develop gangrene each year, and use the cost code 173.01 (Raynaud's with gangrene) then the fol-lowing calculations can be preformed.

330 million (The number of people in the US) * 4% of population (The approximate percent of the population with Raynaud's) * \$9,697 (Cost per treatment of Raynaud's with gan-

grene)
* 1/5 (Percent of Raynaud's suffers that get gangrene

*1/5 (Percent of Raynaud's suffers that get gangerie each year) = \$25.6 billion year in the treatment of resulting gan-grene disease alone. This does not account for the societal impact of the discomfort and pain nor does it account for other, non gangrene complications result-ing from this disease.


Prof. Steven S. Saliterman


Prof. Steven S. Salite


man


Medical Device Solution


The first iteration of our design will include two LED panels which emit a 430nm wavelength of light, which triggers the vessels to widen thus reducing the symptoms of Raynaud's. This wavelength and its effects on vessels was shown by Sikka in "Melanopsin mediates light-dependent relaxation in blood vessels" which demonstrated efficacy of blue light to vasodi-late in rat aortas, however this has not been shown in humans. This device is meant to be an initial exploratory device. After the IRB procedures, if we have proof that this treatment method provides promising results in human studies, we seek to adapt this proto-type to a design that is in the form of gloves. These gloves will come with linings containing micro LEDS emitting light in the 430nm regime or have fiber optics to deliver the light. This design will allow users to stay on the move while still receiving treatment.






















Techniques





Student Machine Shop Waterjet Cutter

Prof. Steven S. Saliterman

Parts Ready for Bending







After Bending in Brake


Prof. Steven S. Saliterman


After Powder Coat Finish











Clinical Trail Rehearsing



Next Steps

Prof. Steven S. Saliterman

- See *Selecting a Medical Device Project*.
- See slide set *Clinical Problem Selection*.
- See *Clinical Problem Selection Worksheet*.
- Next week each team will present its Worksheet Discovery & Ideation progress.
- The week after, you will present your *Worksheet* Investigative Phase items.
- Begin work on your project and poster (I will provide a poster template).